Monte Rosa reports Q2 2026 results as MGD pipeline advances on three fronts
Monte Rosa completed enrollment in its MRT-8102 cardiovascular study, activated two other Phase 2 trials, and said cash on hand should fund operations into 2029.
Monte Rosa Therapeutics said on August 6, 2026 that it has completed enrollment and dosing for all subjects in the GFORCE-1 Phase 1 study of MRT-8102 in individuals with elevated cardiovascular disease risk (NCT07119125)1. The company said the study tested multiple dose levels over four weeks of treatment plus four weeks of safety follow-up, meant to speed dose selection across atherosclerotic cardiovascular disease, gout, and hidradenitis suppurativa, with a readout expected in the second half of 20261. Earlier data disclosed in January showed an 85% median reduction of CRP levels after four weeks of MRT-8102 treatment in subjects with elevated CVD risk1.
The company plans to start three more MRT-8102 studies: a Phase 2b trial in patients with elevated atherosclerotic risk and cardiometabolic syndrome, expected to begin in the second half of 2026 and evaluating 12 weeks of treatment plus an open-label extension1, a gout study expected to start in the fourth quarter of 2026 or first quarter of 2027, testing whether the drug prevents recurrence of gout flares after acute flares are treated1, and a hidradenitis suppurativa study expected to begin in the first half of 20271.
Two other Phase 2 studies have already been activated. Novartis, Monte Rosa's collaborator, started a Phase 2 study of the VAV1-directed molecule MRT-6160 (DDY391) in Sjögren's disease1, registered as "A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease" (NCT07737743)1. Separately, Monte Rosa activated the MODeFIRe-1 Phase 2 study of MRT-2359, which will enroll up to 25 patients to test the drug with apalutamide in metastatic castration-resistant prostate cancer patients carrying androgen receptor mutations1.
On finances, the company reported cash, cash equivalents, restricted cash, and marketable securities of $626.0 million as of June 30, 2026, down from $671.2 million at the end of March 20261, and said this is expected to support operations into 20291.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.